Marker Therapeutics Inc (MRKR)

[Sugarshaker]

This article was posted today from AstraZeneca,
Durvalumab is being evaluated under a broad development program across multiple tumor types (including lung, bladder, head & neck and other cancers), stages of disease, and lines of therapy both as monotherapy and in combination. Of late, AstraZeneca has been looking to build its immuno-oncology portfolio and pipeline with strategic licensing and acquisition deals. The company’s target is to launch at least six new medicines between 2014 and 2020.